Online reviews of GLP-1 medicines often focus on weight change, appetite, side effects, or satisfaction with a provider. A prescriber needs something more precise. They need a factual account of your experience, including timing, symptoms, medical context, and what changed over time.
Start with the medicine name. Include the brand and active ingredient if known, the form, the start date, and whether it was prescribed for diabetes, weight management, or another reason. If you used more than one product, separate them clearly. Do not describe everything as Ozempic or a GLP-1 if the actual product was different.
What to include in your experience
Record appetite changes, fullness, nausea, vomiting, diarrhoea, constipation, reflux, abdominal pain, injection-site reactions, fatigue, mood changes, sleep changes, and blood sugar changes if relevant. Include whether symptoms were mild, disruptive, severe, improving, or worsening.
Weight change can be relevant, but it should not be the only measure. Note hydration, ability to eat regular meals, energy, bowel habits, exercise tolerance, and whether symptoms affected work, caring responsibilities, or daily routines.
If you stopped attending follow-up, missed doses, had supply interruptions, changed provider, or received unclear instructions, include that history without embarrassment. Prescribers are used to practical complications; incomplete information is more risky than imperfect use.
Keep the review factual
A review is not a treatment plan. Do not use your past response, someone else's result, or a star rating to decide whether to restart, stop, switch, increase, or combine medicines.
Seek urgent advice for severe abdominal pain, repeated vomiting, dehydration, fainting, severe allergy symptoms, confusion, or low blood sugar symptoms. For less urgent but persistent side effects, contact the prescriber rather than waiting until the next milestone.
The most helpful review is calm and specific: what you used, what happened, when it happened, what else was changing, and what questions remain.